• 1
    Zeilhofer HU. The glycinergic control of spinal pain processing. Cell Mol Life Sci 2005;62:202735.
  • 2
    Zeilhofer HU. Loss of glycinergic and GABAergic inhibition in chronic pain–contributions of inflammation and microglia. Int Immunopharmacol 2008;8:1827.
  • 3
    Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009;141:2338.
  • 4
    Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:7538.
  • 5
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Clonazepam open clinical treatment trial for myofascial syndrome associated chronic pain. Pain Med 2000;1:3329.
  • 6
    Harkins S, Linford J, Cohen J, Kramer T, Cueva L. Administration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study. J Craniomandib Disord 1991;5:17986.
  • 7
    Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003;26:10734.
  • 8
    Gremeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC et al. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 2004;108:517.
  • 9
    Munro G, Ahring PK, Mirza NR. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009;30:4539.
  • 10
    Zeilhofer HU, Mohler H, Di Lio A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol Sci 2009;30:397402.
  • 11
    Zeilhofer HU, Witschi R, Hosl K. Subtype-selective GABAA receptor mimetics–novel antihyperalgesic agents? J Mol Med 2009;87:4659.
  • 12
    Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 2007;53:81020.
  • 13
    Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50:291313.
  • 14
    Barnard EA. The molecular architecture of GABA-A receptor. In: Mohler H (eds). Pharmacology of GABA and Glycine neurotransmisssion. Springer, Berlin, 2001;7999.
  • 15
    Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796800.
  • 16
    Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:1314.
  • 17
    Knabl J, Witschi R, Hosl K, Reinold H, Zeilhofer UB, Ahmadi S et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008;451:3304.
  • 18
    Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 2011;60:62632.
  • 19
    Atack JR. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci 2010;2:33160.
  • 20
    Hindmarch I, Gudgeon AC. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol 1980;10:14550.
  • 21
    Oblowitz H, Robins AH. The effect of clobazam and lorazepam on the psychomotor performance of anxious patients. Br J Clin Pharmacol 1983;16:959.
  • 22
    Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87107.
  • 23
    Deglon J, Thomas A, Daali Y, Lauer E, Samer C, Desmeules J et al. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J Pharm Biomed Anal 2011;54:35967.
  • 24
    Loscher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 2007;48:124558.
  • 25
    Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 1996;37:72835.
  • 26
    Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990;29:16977.
  • 27
    Atack JR. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. CNS Neurosci Ther 2008;14:2535.
  • 28
    Atack J, Wafford K, Street L, Dawson G, Tye S, Van Laere K et al. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J Psychopharmacol 2011;25:31428.